Abstract: A positioning frame for supporting a patient to facilitate different surgical approaches to the spine includes a main support beam, first and second support structures, a torso-lift support, and a pelvic-tilt support. The main support beam has a first end, a second end, and a length extending between the first and second ends. The main support beam defines an axis of rotation relative to at least a first support structure and a second support structure, and the axis of rotation substantially corresponds to a cranial-caudal axis of the patient when the patient is supported on the positioning frame. The first and second support structures support the main support beam, and space the main support beam from the ground. The torso-lift support is attached to the main support beam, and is configured to pivot a chest support plate between at least a first position and a second position to move the torso of the patient between an unlifted position and a lifted position.

Abstract: An exoskeleton apparatus includes a base unit, a support unit, and upper and lower arm units. The support unit is rotatable about a vertical first axis relative to the base unit. The upper arm unit includes a linking axle, a main arm that has a connecting end rotatable about a horizontal second axis, and a linkage mechanism for rotating the linking axle relative to the main arm about a horizontal third axis. The lower arm unit is rotatable relative to the upper arm unit, and includes a lower arm set co-rotatably coupled to the linking axle, a hand-receiving seat rotatably connected to the lower arm set, and a lower arm receiving seat connected to the hand-receiving seat, and a drive member for rotating the hand-receiving seat about a horizontal fourth axis.

Abstract: A leg support exoskeleton is strapped on as a wearable device to support its user during squatting and/or lunging. The exoskeleton includes a knee joint connected to a first link and a second link, which is configured to allow flexion and extension motion between the first link and the second link. A force generator has a first end that is rotatable connected to the first link. A constraining mechanism is connected to the second link and has at least two operational positions. In a first operational position, the second end of the force generator engages the constraining mechanism, where the first link and the second link flex relative to each other. In a second operational position, the second end of the force generator does not engage the constraining mechanism; the first link and the second link are free to flex and extend relative to each other.

Abstract: A method of performing a fit test on an actuator unit coupled to a user. The method includes determining a first configuration of the actuator unit generated in response to actuating the actuator unit while the user is performing one or more movements for the fit test; determining a change from the first configuration of the actuator unit while the user is performing the one or more movements for the fit test; determining that the change from the first configuration corresponds to an improper fit of the actuator unit coupled the user; and generating an improper fit indication that indicates improper fit of at least leg actuator units coupled the user.

Abstract: A braking system for a rollator with a frame includes an adjustable handle to be installed on a right subframe or a left subframe of the frame of the rollator, a bracket fixedly connected to the handle, a lever rotatably connected to the bracket, a lock movably connected to the bracket and configured to fix the lever in a locked position when the lock is moved relative to the bracket once the lever is rotated toward the frame, and a wire operably connected between the lever and a brake on the frame of the rollator, such that the wire applies the brake when the lever is rotated toward the bracket and when the lever is fixed in the locked position.

Abstract: An automated walker assembly includes a housing having a perimeter wall with a front side, a rear side, a first lateral side and a second lateral side. A plurality of wheel mounts is attached to the housing and a plurality of wheels is attached to the wheel mounts. A pair of handles is attached to the housing for gripping by a user of the assembly. A plurality of drive assemblies is mounted to the housing to control the housing. The drive assemblies include a propulsion drive mechanically coupled to at least one of the wheels and a direction drive is mechanically coupled to at least one of the wheels to define a directional wheel. The propulsion and direction drives propel the assembly over a ground surface. An interface electrically coupled to each of the drive assemblies selectively actuates each of the drive assemblies.

Abstract: An elongate hollow tube having two or more fidgets molded onto or attached to an outside surface of said tube is described. The tube can be slipped over a smooth elongated base object, such as a pencil or similar object, to provide manipulatives for students.

Abstract: Provide is an air massage device including a plurality of air bags; an air pump 31 for supplying air into each of the air bags; solenoid valves 32 for switching on-off of air supply into each of the air bags; and a control part for changing an electric input value into the air pump 31 and an amount of the supplied air into each of the air bags per unit time to open and close each of the solenoid valves 32 so as to correspond to this change of the amount of the supplied air.

Abstract: Massage mechanisms of a massage machine individually include a pair of left and right treatment members provided along a height direction of the massage machine. A first massage mechanism is disposed on a relatively upper side, and a second massage mechanism is disposed on a relatively lower side. A control means that controls operations of the first and second massage mechanisms. The control means controls advancing/retreating drive portions such that the treatment members of the first massage mechanism and the treatment members of the second massage mechanism advance or retreat at speeds different from each other such as with a time lag.

Abstract: A massage system includes a chair type massage machine that performs a massage on a person to be treated, a head mounted display (head worn type display device) that is worn on a head portion of the person to be treated, and a controller, which, when the massage is being performed by the massage machine on the person to be treated, makes a video image, including a moving image of a virtual practitioner performing the massage, be displayed on the head mounted display.

Abstract: A lung gas exchange device includes a front housing, at least one strap configured to affix the front housing to an anterior neck of a user, a vibration device positioned within the front housing, a wear plate configured to transfer vibration from the vibration device to the anterior neck of the user, a power source configured to provide power to the vibration device, a power control mechanism configured to allow a user to turn on and off the vibration device; and a central processing unit board connected to the power control mechanism, the power source, and the vibration device.

Abstract: An adaptor for coupling with a medical container, including: a tubular body receiving a pierceable elastomeric piece, defining an inner cavity of the adaptor, the pierceable elastomeric piece being movable within the tubular body between a first position, in which a distal part of the pierceable elastomeric piece forms a seal of the cavity, and a second position, proximally spaced from the first position, in which the distal part opens the seal of the cavity, an air inlet, a filtering system for filling the inner cavity with decontaminated air, and a gripping member for securing the adaptor to the medical container. Also, an assembly comprising such an adaptor and a medical container.

Abstract: A container system having at least two containers, wherein the container system comprises a light member which is configured to provide information through the emission of light, wherein the container system is configured to provide or trigger the light member to provide the information through the emission of light when a step related to preparing a mixture of contents of the containers is performed. In particular, triggering occurs when the containers are separated from one another and/or when a fluidic connection is created between the containers.

Abstract: A medicament transport system includes a syringe adapter assembly; and a vial adapter assembly including a base defining an opening having a seal member disposed therewithin, a stem extending from the base and defining a lumen therethrough and an opening through a wall thereof, a needle shuttle valve slidably disposed within the lumen of the stem and supporting a transfer needle and a vacuum needle; and a vacuum cup slidably supported on the stem, wherein a vacuum chamber is defined in the space between the base, the stem and the vacuum cup. The medicament transport system includes a condition where the transfer needle and the vacuum needles penetrate the seal member of the vial adapter assembly, and the vacuum cup is moved to draw a vacuum through the vacuum needle. An automation system is provided that utilizes a medicament transport system for forming a medicament solution from a liquid/non-liquid solution.

Abstract: The invention relates to a method and a system for synthesizing a medical preparation, a peristaltic pump being used for pumping liquid from a plurality of source containers. According to the invention, the individual metering steps are verified by a weighing process, even the metering of micro-amounts being verifiable.

Abstract: Provided is a die roll for manufacturing softgels, a softgel, and methods for producing a softgel. The die roll includes a die roll surface and a pocket defined therein. The pocket includes a floor, an interior sidewall surface, a chamfer, and an exterior sidewall surface. The floor is recessed relative to the die roll surface and the interior sidewall surface is connected to the floor and extends above the die roll surface to the chamfer. The pocket also includes a landing surface that is elevated from the die role surface and connects the chamfer to the exterior sidewall surface of the pocket. The landing surface includes a taper (such that the landing surface tapers inwardly towards the pocket floor) and a radius (such that the landing surface is not flat). Also provided is a softgel having a trailing edge thickness that is at least about 40% the thickness of the softgel wall thickness.

Abstract: A solution is proposed for dispensing substances to be taken by a user. A corresponding dispensing device comprises a memory for storing an indication of a taking plan of a plurality of doses of one or more substances, the taking plan comprising an indication of a taking time of each dose, a plurality of compartments each one for containing one of the doses, a signaling unit for providing a taking notice of each dose in response to the corresponding taking time, a pushbutton for releasing the dose corresponding to each taking notice from the corresponding compartment in response to a releasing command; the dispensing device comprises a plate having a collecting surface in a central zone thereof, the compartments being arranged in a peripheral zone of the plate and the pushbutton facing towards the central zone of the plate for collecting the doses released thereby onto the collecting surface.

Abstract: A composition of matter includes one or more functionalized vinylbenzyl components of the formula covalently connected to one or more R functional components; the one or more R functional groups selected from a group including one or more hydroxyl methyl (—CHOH—) moieties and/or derivatives thereof, one or more ethoxy (—CH2—CH2—O—) moieties and/or derivatives thereof, end one or more benzene (C6H6) and/or derivatives thereof; and ether links that connect the functionalized vinylbenzyl components and the R functional components.

Abstract: This invention relates to oral care compositions comprising zinc phosphate, a first source of stannous (e.g., stannous fluoride); and a second source of stannous, wherein the second source of stannous comprises stannous pyrophosphate, as well as to methods of using and of making these compositions.

Abstract: To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair. An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.

Abstract: The present invention belongs to the fields of pharmaceuticals and cosmetics, and concerns on the one hand a medicament for the inhibition of and refers also on the cosmetic, non-therapeutic use for the treatment of hyperpigmentation, particularly induced by sun light radiation, preferably induced by visible light radiation.

Abstract: The invention relates to the cosmetic use, as a deodorant active agent, of spiculisporic acid in free form, partially or fully neutralised by at least one mineral and/or organic base. The invention also relates to a cosmetic method for treating human body odours, in particular the armpits or feet, in which at least one spiculisporic acid as defined above or a composition containing same in a physiologically acceptable medium is applied to the human keratin material.

Abstract: The present invention is directed to a skin-mimicking emulsion comprised of polyosides, minerals, inositol polyphosphate or phytic acid, polysaccharides, triglycerides, polyols, alpha or beta hydroxy acids, phospholipids, phytosterols, vitamins, fatty alcohols, essential lipids, amino acids, and water. All of the inventive ingredients in combination are design to be similar to those found in skin and are combined to form a lamellar structure for maximum efficacy. The composition does not include any of the components usually found in conventional emulsions, such as synthetic preservatives, surfactants, fragrances, colorants, acrylic polymers, gelling agents, sequestrants, and EDTA as such ingredients would be irritating to the skin.

Abstract: A deodorant stick comprising: at least about 25% of a liquid triglyceride; at least one antimicrobial; a primary structurant with a melting point of at least about 50° C.; and less than 8% of secondary structurants having a melting point of at least about 60° C.; said stick being free of an aluminum salt; and said stick having a hardness from about 80 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: A personal care composition includes a structured cleansing phase; a benefit phase including triglycerides, a cationic deposition polymer, and anionic microcapsules; and a carrier; and methods relating thereto.

Abstract: The present invention relates to a cosmetic composition comprising guacatonga extract (Casearia silvestris), aroeira extract (Schinus tere-binthifolius raddi) and cosmetically acceptable adjuvants, for preventing and/or treating signs of skin aging. It further relates to the use of guagatonga extract (Casearia silvestris) and aroeira extract (Schinus terebinthifolius raddi) in the preparation of a cosmetic composition for preventing and/or treating signs of skin aging, as well as the use of this composition for simultaneously increasing tropoelastin, increasing the lysyl exidase (LOX) enzyme and reducing the activity of elastase in the dermis. The invention relates to a method of preventing and/or treating signs of skin aging, which comprises applying said cosmetic composition to the skin. Finally, the invention relates to a method of preparing said composition according to the present invention.

Abstract: Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract.

Abstract: Disclosed is the use of partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to prevent skin aging. More specifically the invention discloses the anti-collagenase, anti-elastase, anti-glycation activity and enhancement of TGF-?, epidermal growth factor and hyaluronic acid expression in human dermal fibroblasts, of extracellular metabolites isolated from Bacillus coagulans MTCC 5856.

Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

Abstract: The invention relates to the use of an oral bolus for drying-off cattle, preferably daily cattle, as well as methods of improving/facilitating the drying-off of cattle, reducing the milk production in pregnant and/or lactating cattle, decreasing milk accumulation in the udder of cattle, increasing the daily lying time of cattle, inducing a mild and temporary metabolic acidosis in cattle, reducing the dry matter intake (DMI) in cattle and/or reducing urine pH in cattle, preferably dairy cattle, comprising administering to such cattle at least one oral bolus, preferably on the last milking day and/or before dry-off.

Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as analgesics including cannabinoids, menthol and anesthetic in a composition formulated to be administrable to a non-human animal rectally as a suppository.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.

Abstract: The present disclosure is broadly concerned with petrolatum-based compositions as a suspension matrix for the active ingredients. The disclosure is also concerned with processes for forming stable emulsions of active ingredients in petrolatum.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.

Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

Abstract: The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a second coating comprising a second active ingredient.

Abstract: The present patent application relates to coated particles. These coated particles show improved properties when used in compressed tablets.

Abstract: The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: The present invention provides a system enabling the oral delivery of therapeutics derived from polyunsaturated fatty acids (PUFAs), their metabolites and derivatives, including, eicosanoids, prostaglandins, prostacyclins, leukotrienes, resolvins, endocannabinoids, thromboxanes, epoxyeicosa-trienoic acids (EETs), hydroxyeicostetraenoic acids (HETEs), and CMX-020. The delivery system includes a vehicle comprising a purified docosahexaenoic acid (DHA) in triglyceride or ester form; a purified eicosapentaenoic acid (EPA) in triglyceride or ester form; a combination of DHA, EPA in either triglyceride or ester forms; or a modified DHA, EPA, or omega-3 fatty acid analog; and optionally, an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH/tonicity adjustment agent.

Abstract: A composition for treating the symptoms of a hangover. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. The composition includes a therapeutically effective amount of cannabidiol, an antioxidant blend, a detox blend, and a hydration blend. The antioxidant blend includes prickly pear, acai berry extract, and taurine. The detox blend includes milk thistle, dihydromyricetin, glutamine, branched chain amino acids, inositol, and pepper. The hydration blend includes electrolytes, vitamins, and N-acetyl cysteine.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.